A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops

Purpose: We report a case where tacrolimus eye drops may have alleviated immune checkpoint inhibitor (ICI)-related conjunctivitis attributed to nivolumab. Observations: A 61-year-old female complained of conjunctival hyperemia and eyelid swelling in both eyes. The patient was previously undergoing t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ayaka Kawaguchi, Hayato Tanaka, Hitoshi Tabuchi, Kei Nakai, Atsuki Fukushima
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	American Journal of Ophthalmology Case Reports
Subjects:	Tacrolimus eye drops Immune checkpoint inhibitor-related conjunctivitis Immune-related adverse events nivolumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451993625000210
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report
by: Chang Jiang, et al.
Published: (2025-02-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

A case of eruptive keratoacanthomas and lichen planus secondary to nivolumab treatment for stage IV melanoma
by: Daniel S. Alicea, MS, et al.
Published: (2025-03-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

Identification of tacrolimus-related genes in familial combined hyperlipidemia and development of a diagnostic model using bioinformatics analysis
by: Yuan Xu, et al.
Published: (2025-02-01)

The management of bacterial conjunctivitis
by: Anna Kiełczewska, et al.
Published: (2025-02-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
by: Maximilian Riedel, et al.
Published: (2025-01-01)

Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade
by: Victoria E. Stefan, et al.
Published: (2024-11-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Forced degradation of tacrolimus and the development of a UHPLC method for impurities determination
by: Peterka Tanja Rozman, et al.
Published: (2019-09-01)

Pharmacological Treatment of Presbyopia Using Pilocarpine 1.25% Eye Drops
by: Seyed Abolghasem Mousavi, et al.
Published: (2024-12-01)

Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics
by: Haruno Oku, BS, et al.
Published: (2025-01-01)

Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population
by: Wang RH, et al.
Published: (2025-02-01)

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients
by: Alan D. Kaye, et al.
Published: (2024-12-01)

Tacrolimus trough level and oxidative stress in Tunisian kidney transplanted patients
by: Mariam Ammar, et al.
Published: (2024-12-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

Case report: Diagnosis of impaired consciousness in a cancer patient using immune checkpoint inhibitors
by: Daniel Cathalifaud, et al.
Published: (2025-01-01)

Noun juxtaposition for predication, possession, and conjunction: Beyond ambiguity avoidance
by: Shogo Mizuno
Published: (2025-01-01)

Evaluation of efficacy and safety of generic tacrolimus (Suprotac®) compared to reference tacrolimus (Prograf<sup>®</sup>) in kidney transplantation: a phase IV study
by: Behzad Einollahi, et al.
Published: (2025-01-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Sequentially Activated Smart DNA Nanospheres for Photoimmunotherapy and Immune Checkpoint Blockade
by: Yu Chen, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report
by: Tomoyuki Otsuka, et al.
Published: (2025-02-01)

Case report: Multi-organ injuries induced by tislelizumab
by: Man Yuan, et al.
Published: (2025-02-01)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01)